SR9009, also known as Stenabolic, is an agonist of the Rev-ErbA protein. It has exhibited the potential ability to increase cardiovascular endurance, stimulate fat loss, improve heart health, and decrease body weight, inflammation, and cholesterol in mice.
SR9009 has also prevented cellular senescence, decreased the viability of cancer cells, and shrunk the size of atherosclerotic plaque in animal studies. Research has further indicated that SR9009 is lethal to chemo-sensitive and chemo-resistant small-lung cancer cells.
Behemoth Labz sells SR9009 for laboratory and research purposes only.
May Also Improve LDL Cholesterol and Triglycerides [R]
Appears to Drastically Improve Cardiovascular Endurance [R]
Keep contents sealed and stored in a cool dry place. Items are shipped in a plain envelope or bubble mailer within 24-48 hours (or the next business day)
Stenabolic, otherwise known as SR9009, is a PPAR delta receptor agonist similar to Cardarine.
It was initially researched by Professor Thomas Burris of the Scripps Research Institute for its ability to increase mitochondria in skeletal muscle tissue.
CAS Number is stated as 1379686-30-2
Molar Mass is 437.94026 g·mol−1
It has a Chemical Formula of C20H24ClN3O4S
IUPAC Name is ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate
The Cardarine for sale from Behemoth Labz is 3rd party tested for the utmost purity.
What is SR-9009?
SR9009 is a synthetic REV-ERB agonist. REV-ERBs are proteins that regulate the circadian rhythm, or the body’s internal 24-hour clock. Circadian rhythms, in turn, control various body functions, including sleep-wake cycles, fat burning and storage, and body temperature. [R][R]
SR9009 was initially discovered in 2012 at Scripps Research Institute. In one of its first studies, SR9009 demonstrated the potential ability to stimulate significant fat loss and reduce body weight. Mice injected with Stenabolic for a week lost weight due to a reduction in fat mass. [R]
Stenabolic might also protect heart health in various ways. Besides reducing the size of atherosclerotic plaque in blood vessels, SR9009 reduced blood levels of total cholesterol and triglycerides in mice. High levels of cholesterol and triglyceride are harmful to the heart. [R][R]
Recent research has explored SR9009’s anti-cancer effects. A pre-clinical study has found that it potentially inhibits chemo-sensitive and chemo-resistant small lung cancer cells. Another study has shown that Stenabolic may potentially exert a cytotoxic effect on different types of cancer cells. [R][R]
How does SR-9009 Work?
SR9009 works by potentially binding/activating REV-ERBα in the body. REV-ERBα is one of two REV-ERB agonists, the other being REV-ERBβ. Research has indicated that REV-ERBα is highly expressed in oxidative skeletal muscle and that its deficiency in muscle leads to compromised exercise capacity. [R]
Experiments have indicated that REV-ERBα activation improves muscle oxidative function. In addition, the pharmacological activation of this REV ERB increases exercise capacity. All the effects linked to SR9009 stem from its potential activation of REV-ERBα.
SR-9009 Vs SR-9011
SR9009 and SR9011 are both synthetic REV-ERB agonists. Effects of both observed in vitro and in vivo animal studies include increased basal oxygen consumption, decreased lipogenesis, cholesterol, and bile acid synthesis in the liver, and increased fatty acid oxidation in the liver. [R]
The observed increase in energy expenditure and decrease in fat mass make the REV-ERB agonists SR9009 and SR9011 promising candidates for the treatment of several metabolic disorders. Still, neither of them is approved for therapeutic use anywhere in the world. [R][R]
Various animal and cell-based studies have been conducted on Stenabolic. These have demonstrated the potential effects of SR9009 on body weight, cellular senescence, heart health, physical endurance, cancer cells, and sleep/wakefulness patterns.
All the information presented below is for educational purposes only and does not constitute medical advice. It is drawn from preclinical research.
Stenabolic and Weight Loss
In an animal study, SR9009 treatment caused weight loss in three mice groups.
The first group consisted of mice with normal body weight. All the subjects of this group lost significant weight after being administered SR9009 for 7 days. Researchers conducting the study noted that the weight reduction was due to a decrease in fat mass. [R]
The second and third groups were made up of diet-induced and genetically obese mice. In the former group, SR9009 injected for 30 days caused a 60% higher weight loss than in control animals. Genetically obese mice stopped gaining weight after 12 days of Stenabolic treatment.
Stenabolic and Cellular Senescence
Senescence, also known as aging, is the time-related deterioration of body cells. Symptoms of senescence include increased susceptibility to chronic diseases and infection and loss of resistance to internal and external stressors. Senescent cells may also cause heart diseases. [R]
In mouse models of therapy-induced and oncogene-induced senescence, SR9009 counteracted cellular senescence induced by persistent DNA damage. SR9009’s suppressive effects on the aging of cells were mediated by inhibiting ROS levels through the NRF2 pathway. [R]
SR9009 increased the expression as well as the nuclear translocation of NRF2. NRF2 activates the transcription of several antioxidant genes known for counteracting ROS to alleviate senescence. In summary, Stenabolic could suppress senescence in vitro and in vivo.
Stenabolic and Heart Health
SR9009 could potentially improve heart health in various ways.
Mice administered SR9009 for 7 to 10 days had reduced triglycerides and total cholesterol levels at the end of the treatment period. In another study, SR9009 treatment reduced total cholesterol, triglycerides, and LDL cholesterol in mice on a high-cholesterol diet. [R][R]
In another mice study, genetically modified mice susceptible to the hardening of the arteries were administered SR9009 for seven weeks. Results from the study indicate that SR9009 treatment reduced the size of the blood vessel lesions without affecting food intake. [R]
Similarly, in mice with surgically induced heart growth, Stenabolic administered for 14 days reduced heart size and weight. In the same study, Stenabolic injected for 4 weeks improved heart function in both normal as well as genetically modified old mice. [R]
Stenabolic and Cancer
A cell-based study explored the efficacy of SR9009 for the treatment of small-lung cancer cells (SCLC). It found that Stenabolic is specifically lethal to both chemo-sensitive and chemo-resistant SCLC cells, indicating SR9009 as a potential therapeutic strategy in 1st or 2nd-line SCLC treatment. [R]
Another cell-based study went a step further. It found that SR9009 treatment exerts a cytotoxic effect on cancer cells derived from different tumor types, namely brain, leukemia, breast, colon, and melanoma. Another REV-ERBs agonist (SR9011) displayed similar properties.
Notably, while SR9009 and SR9011 are effective against tumor lines, they have little or no toxic effects on normal cells at comparable concentrations. In summary, the anti-tumor activity of these REV-ERB agonists is effective against a broad spectrum of tumors. [R]
Stenabolic and Circadian Clock
Administration of REV-ERB agonists (SR9009 and SR9011) altered circadian behavior and core clock gene expression patterns in hypothalamic mice. The alteration of circadian pattern expression resulted in an increase in energy expenditure.
The circadian clock regulates sleep-wake patterns, metabolism, and various other functions in your body. The results mentioned above thus suggest that SR9009 and SR9011 may hold utility in the treatment of sleep disorders as well as metabolic diseases. [R]
Stenabolic and Wakefulness
Animal studies have indicated that mice injected with SR9009 during the daytime were more active during the day and had less sleep. These studies further establish that SR9009 does not lose efficacy when administered more than once a day, nor does tolerance develop. [R]
Furthermore, through the use of a time response paradigm, it was determined that there is an optimal time for the administration of SR9009 in terms of maximal efficacy. In addition, there was a 12-hour window in which this synthetic REV-ERB agonist elicited a response.
Stenabolic and Inflammation
A mice study has highlighted the anti-inflammatory role of SR9009 in endotoxin-induced inflammation. The study showed that pharmacological activation of REV-ERBα with Stenabolic significantly suppressed the lipolysaccharide (LPS)-induced inflammation in vitro and in vivo. [R]
Stenabolic and Endurance
A mice study was conducted to explore the effects of SR9009 on endurance. One of the study’s groups was administered SR9009 for 30 days and the effects were noted. It was found that mice treated with SR9009 covered more distance and ran for a longer time than controls. [R]
Stenabolic and Anxiety
Stenabolic treatment for 3 to 10 days reduced anxiety-like behavior in mice. SR9009 was administered twice a day for the entire treatment period. Notably, the effects of SR9009 on anxiety reduction were as potent as those of benzodiazepine, a standard anti-anxiety drug. [R]
Frequently Asked Questions
Does SR9009 Have The Potential to Burn Fat?
In multiple animal studies, SR9009 has demonstrated the ability to burn fat. These studies involved normal mice, diet-induced obese mice, and genetically obese mice. All three experienced decreased lipogenesis after SR9009 treatment.
Is SR-9009 a SARM?
SR-9009 is not a selective androgen receptor modulator. It is a synthetic REV-ERB agonist that has demonstrated the ability to reduce fat-storing cells, increase lean muscle mass, and improve cholesterol levels. However, SR 9009 is yet to attract clinical research.
Where to Buy SR-9009 for Sale?
Behemoth Labz is the best place to buy SR-9009 online.
We have been around since 2014, supplying the highest-quality research compounds money can buy. All of our products come with a 100% satisfaction guarantee, free and fast shipping, and a money-back guarantee. We carry SR-9009 liquid, SR-9009 transdermal, and SR-9009 injectable for laboratory research use only.
In various animal and cell-based studies, SR-9009 has exhibited a potential ability to treat obesity, improve heart health and inhibit the action of various cancer cells. This REV-ERB agonist has also demonstrated positive effects on endurance and on lipid and glucose metabolism.
Behemoth Labz doesn’t sell SR-9009 Stenabolic for human consumption.
Behemoth Labz Disclaimer
Please make sure you go through the Terms and Conditions, and please familiarize yourself with it as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.
Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at [email protected] if you are not fully satisfied with the product. Customer satisfaction is our number one priority!
ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.